Home Paragonix Technologies Inc

Paragonix Technologies Inc

    4/26/19: Expansion of Partnership Between Paragonix and the Lung Transplant Foundation To Accelerate Commercialization of Innovative Lung Preservation Technlogies

    Paragonix is currently completing commercial development of the Paragonix SherpaLung™ Preservation System and expects the filing of FDA pre-market notification and European CE clearance by Q4 2019. The Paragonix SherpaLung™ Preservation System is designed to ensure optimal lung preservation during its journey from donor to recipient patient by incorporating medically proven and clinically validated preservation techniques combined with lung inflation pressure control, ensuring stable inflation pressure on the ground or during air transport.

    SherpaPak™ Cardiac Transport Systems and SherpaPerfusion™ Cardiac Transport System Presented at the 38th Annual Meeting of the International Society for Heart and Lung Transplantation

    4/3/18: The SherpaPak™ Organ Transport product line1,2 combines innovative cooling technology with safe, consistent methods for cold ischemic storage and transport of donor organs to recipients for implantation. The SherpaPerfusion™ Cardiac Transport System family of products consists of a single-use, disposable device for hypothermic oxygenated perfusion preservation and transport of donor hearts.

    Paragonix Technologies Inc., Announces Presentation of the SherpaPak™ Organ Transport Systems at ATC

      “We are looking forward to discussing the SherpaPak™ Organ Transport Systems with the clinical community during the ATC.” Paragonix Technologies, Inc. will present the SherpaPak™...